

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
SHARE PURCHASE BY THE TRUSTEE
PURSUANT TO THE SHARE AWARD SCHEME

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. Reference is made to the post-IPO share award scheme of the Company adopted by resolutions passed in the meeting of the shareholders of the Company on 23 November 2020 (the “**Share Award Scheme**”), a summary of the principal terms of which was set out in the Company’s prospectus dated 30 November 2020 (the “**Prospectus**”) and available on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.harbourbiomed.com). Unless otherwise defined herein, capitalised terms used in this announcement have the same meanings defined in the Prospectus.

As disclosed in the Prospectus, according to the Scheme Rules, the Company shall (i) issue and allot Shares to the Trustee under the specific mandate sought from Shareholders during the general meeting and/or (ii) transfer to the Trustee the necessary funds and instruct the Trustee to acquire Shares through on-market transactions at the prevailing market price, so as to satisfy the Awards (in each case as defined in the Prospectus).

During the period from 6 December 2021 to the date of this announcement, the Trustee has purchased an aggregate of 7,700,000 Shares at an average price of approximately HK\$8.22 from the market to hold on trust for the benefit of the Participants pursuant to the Share Award Scheme and the Scheme Rules. The Shares so purchased will be used as awards for the Participants in the Share Award Scheme. Pursuant to the Scheme Rules, notwithstanding that the Trustee is the legal registered holder of the Shares held upon trust pursuant to the Share Award Scheme, the Trustee shall refrain from exercising any voting rights attached to such Shares held by it under the trust.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 30 December 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Mr. Xiaoxiang Chen as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.